Literature DB >> 7397054

Studies on the clinical pharmacology of prazosin. II: The influence of indomethacin and of propranolol on the action and disposition of prazosin.

P Rubin, G Jackson, T Blaschke.   

Abstract

1 The possibility of pharmacodynamic and pharmacokinetic interactions of prazosin with indomethacin and with propranolol have been studied in healthy subjects. 2 In four out of nine individuals indomethacin considerably attenuated prazosin-induced hypotension, but noradrenaline concentrations were unchanged from the day when blood pressure fell greatly. The effect of prazosin in the other five subjects was not influenced by indomethacin. 3 Indomethacin prevented the rise in plasma renin activity seen following administration of prazosin alone. 4 Propranolol did not prevent the syncope associated with the first dose of prazosin. 5 Propranolol affected neither the absorption nor elimination of prazosin. 6 It is concluded that in certain subjects indomethacin can largely prevent the hypotensive effect of parazosin, possible by increasing adrenergic receptor sensitivity. The theoretical possibility that propranolol could influence prazosin disposition or syncope was not substantiated.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7397054      PMCID: PMC1430018          DOI: 10.1111/j.1365-2125.1980.tb00499.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

Review 1.  Ambulatory electrocardiography for diagnosis and treatment of cardiac arrhythmias.

Authors:  D C Harrison; J W Fitzgerald; R A Winkle
Journal:  N Engl J Med       Date:  1976-02-12       Impact factor: 91.245

Review 2.  Prazosin: a review of its pharmacological properties and therapeutic efficacy in hypertension.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-09       Impact factor: 9.546

Review 3.  The role of serotonin and dopamine in hypothalamic-pituitary function.

Authors:  G A Smythe
Journal:  Clin Endocrinol (Oxf)       Date:  1977-10       Impact factor: 3.478

4.  Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine.

Authors:  J D Peuler; G A Johnson
Journal:  Life Sci       Date:  1977-09-01       Impact factor: 5.037

5.  Hemodynamic drug interactions: the reduction of oxyphenbutazone clearance by dl-propranol in the dog.

Authors:  R A Branch; D G Shand; A S Nies
Journal:  J Pharmacol Exp Ther       Date:  1973-10       Impact factor: 4.030

6.  The reduction of lidocaine clearance by dl-propranolol: an example of hemodynamic drug interaction.

Authors:  R A Branch; D G Shand; G R Wilkinson; A S Nies
Journal:  J Pharmacol Exp Ther       Date:  1973-02       Impact factor: 4.030

7.  Modification of antihypertensive effect of beta-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.

Authors:  V Durão; M M Prata; L M Gonçalves
Journal:  Lancet       Date:  1977-11-12       Impact factor: 79.321

8.  Prostaglandins are overproduced by the kidneys and mediate hyperreninemia in Bartter's syndrome.

Authors:  F C Bartter; J R Gill; J C Frolich; R E Bowden; J W Hollifield; N Radfar; H R Keiser; J A Oates; H Seyberth; A A Taylor
Journal:  Trans Assoc Am Physicians       Date:  1976

9.  Suppression of plasma renin activity by indomethacin in man.

Authors:  J C Frölich; J W Hollifield; J C Dormois; B L Frölich; H Seyberth; A M Michelakis; J A Oates
Journal:  Circ Res       Date:  1976-09       Impact factor: 17.367

10.  Prostaglandin synthetase inhibitors in Bartter's syndrome. Effect on immunoreactive prostaglandin E excretion.

Authors:  R E Bowden; J R Gill; N Radfar; A A Taylor; H R Keiser
Journal:  JAMA       Date:  1978-01-09       Impact factor: 56.272

View more
  16 in total

Review 1.  Nifedipine interactions in hypertensive patients.

Authors:  A Salvetti; A Magagna; B Abdel-Haq; M Lenzi; R Giovannetti
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  Clinical experience with guanfacine in long-term treatment of hypertension.

Authors:  P Jerie
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

3.  Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients.

Authors:  A Salvetti; F Arzilli; R Pedrinelli; P Beggi; M Motolese
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 4.  Interactions of NSAIDs with diuretics and beta-blockers mechanisms and clinical implications.

Authors:  J Webster
Journal:  Drugs       Date:  1985-07       Impact factor: 9.546

5.  Acute effect of an alpha 1-adrenoceptor antagonist on urinary sodium excretion, plasma atrial natriuretic peptide, arginine vasopressin, and the renin-aldosterone system in healthy subjects.

Authors:  T Tomiyama; T Baba; S Murabayashi; T Ishizaki
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 6.  Do nonsteroidal anti-inflammatory drugs interfere with blood pressure control in hypertensive patients?

Authors:  K Radack; C Deck
Journal:  J Gen Intern Med       Date:  1987 Mar-Apr       Impact factor: 5.128

7.  Prazosin first dose phenomenon during combined treatment with a beta-adrenoceptor blocker in hypertensive patients.

Authors:  P Seideman; A Grahnén; K Haglund; B Lindström; C Von Bahr
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 8.  The problems and pitfalls of NSAID therapy in the elderly (Part II).

Authors:  A G Johnson; R O Day
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

9.  Clinical pharmacological studies with prazosin during pregnancy complicated by hypertension.

Authors:  P C Rubin; L Butters; R A Low; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1983-11       Impact factor: 4.335

10.  Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol.

Authors:  L A Ferrara; M Mancini; T Marotta; F Pasanisi; M L Fasano
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.